The crisis over the contamination of valsartan and other angiotensin II receptor blockers with carcinogenic nitrosamines continued to unfold, with the US FDA quickly approving a 17th generic version of the blood pressure medication in hopes of alleviating shortages, while a bipartisan request for a House committee staff briefing on the issue suggests there could be a legislative response on the horizon.
In the meantime, FDA criminal investigators procure some interesting equipment and services in their efforts to nab drug counterfeiters.





